Thursday, March 31, 2016

Treatment for late-stage prostate cancer patients: getting closer to a solution (via ERC)

Prostate cancer is fuelled through the activation, by the hormone testosterone, of a specific protein called androgen receptor. To halt the progression of the disease, drugs are used to inhibit this receptor. However, after a few years, patients become resistant to the treatment, due to mutations and other modifications in the protein. By studying its 3D structure and its motions, ERC grantee Prof. Xavier Salvatella is looking for new cancer therapies that would bypass these mutations.

from EUROPA - Syndicated Research News Feed

No comments:

Post a Comment